Board and management team
CBD Solutions board:
Sten Mortstedt, Chairman
Sten Mortstedt, a businessman and philanthropist, has a consistent track record during a period of over 40 years, of building profitable and sustainable businesses. He currently serves as Executive Director of CLS Holdings plc, a pan-European property company which he established in 1987 and took to a listing on the main market of the London Stock Exchange in 1994. In addition to his focus on property, he has been commercially active in a number of investment areas outside the property arena and has seen a number of the companies in which he has invested through to successful stock exchange listings or trade sales.
Björn Bloth, Vice Chairman
Björn Bloth, MD, PhD, Associated Professor, works as scientific and medical advisor to several foundations and organisations. He has a PhD in Medical microbiology and immunology and has also a board certification in Internal medicine. He has been practicing medicine for many years.
Ingvar Dahlqvist, member
Ingvar Dahlqvist has a BA in economy. He has for several years worked in Europe for a French industrial group as a Business Controller and Financial Director, for market development and as a Managing Director and is today a member and a chairman of the board of a number of Swedish and French companies. He is also the chairman of the Parkinson association in the south of Sweden and also a member of the election committee of the national Parkinson association in Sweden.
Angela Crawley, member
Angela Crawley has a BA in Psychology and a MA in Psychotherapy. She has a private practice in the London area.
Anna Seeley, member
Anna Seeley (née Mortstedt) is a qualified Chartered Surveyor and has worked in the property industry for over 20 years. She has held various positions within the property departments of General Electric, BT Group and is currently Non-Executive Vice Chairman of CLS Holdings Plc. She holds a degree in property valuation and finance from City University and is the daughter of Mr Sten Mörtstedt. Anna is also on the board of directors of the Sten & Karin Mortstedt Family and Charity Trust.
Samuel Svensson, CEO
Samuel Svensson PhD (Pharmacology) has been working for more than 10 years at Neuroscience AstraZeneca R&D Södertälje, Sweden responsible for the development of the amyloid selective PET radiotracer 18F-AZD4694 recently acquired by Navidae Biopharmaceuticals. He is a cofounder and Senior Principal Scientist at the Alzecure Research foundation and chairman at BioPercept AB. Samuel Svensson is an adjunct Professor in Pharmacology at Div for Drug Research, Linkoping University.